Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia

Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: McMahon, Christine M., Canaani, Jonathan, Rea, Bryan, Sargent, Rachel L., Qualtieri, Julianne N., Watt, Christopher D., Morrissette, Jennifer J. D., Carroll, Martin, Perl, Alexander E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2019
Konular:
Stimulus Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538870/
https://ncbi.nlm.nih.gov/pubmed/31122910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018029496
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller